Abstract
This study have investigated the clinical status of subjects with type 2 diabetes mellitus starting dipeptidyl peptidase-4 inhibitors (DPP4i) and examined the efficacy of multiple oral hypoglycemic agents (OHA) with DPP-4i as add-on therapy. Subjects treated with DPP-4i as add-on therapy accounted for 61.5 % of 1,656 patients that started with DPP-4i and completed follow-up for six months. The percentages of the patients treated with one, two or three OHAs agents combined with DPP-4i were 31, 50 and 18 %, respectively. A three-drug combination, i.e. sulfonylureas, biguanides and DPP-4i was the most frequently used pattern of multiple drugs with DPP-4i and accounted for 35 % of all multiple regimen. The mean HbA1c improved significantly from 7.75±1.00 % to 6.96±0.92 % after 6 months of DPP-4i combined with OHA treatment. The reduction in the HbA1c level over 6 months did not show a significant difference in the groups with different numbers of OHAs (1-3) with DPP-4i and in the patterns of multiple therapy. These findings suggested that the addition of DPP-4i to multiple OHAs was effective for primary diabetes care.
